Stock events for iRhythm Holdings, Inc. (IRTC)
iRhythm reported Q3 2025 revenue of $192.9 million, a 30.7% year-over-year increase, and a gross margin of 71.1%. iRhythm presented new data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 highlighting the performance of its Zio long-term continuous monitoring in an Asian population and participated in investor conferences. iRhythm provided preliminary Q4 2025 highlights, expecting full-year 2025 revenue to exceed prior guidance and projected revenue of $870-$880 million for full-year 2026. iRhythm announced strong Q4 and full-year 2025 results, with Q4 revenue of $208.9 million and full-year revenue of $747.1 million and achieved its first year of positive adjusted EBITDA and free cash flow in 2025. Multiple senior executives sold shares in early March 2026, totaling approximately $2.29 million in proceeds.
Demand Seasonality affecting iRhythm Holdings, Inc.’s stock price
iRhythm Holdings, Inc. experiences typical revenue seasonality and anticipates its first-quarter revenue to be consistent with these recurring patterns.
Overview of iRhythm Holdings, Inc.’s business
iRhythm Holdings, Inc. is a digital healthcare company focused on creating solutions for detecting, predicting, and preventing disease, operating within the Medical Devices and Instruments industries. Its core business involves the design, development, and commercialization of device-based technology for ambulatory cardiac monitoring services, enabling quicker and more efficient arrhythmia diagnoses. The company's major products and services revolve around its Zio® System, including the Zio Monitor, Zio XT, and Zio AT Systems, as well as the Zio ECG Utilization Software System (ZEUS System) and the Zio Watch (under development).
IRTC’s Geographic footprint
iRhythm Holdings, Inc. is headquartered in San Francisco, California, United States. The company has an international presence, offering its Zio portfolio of cardiac monitoring solutions in Austria, Japan, the Netherlands, Spain, Switzerland, and the United Kingdom.
IRTC Corporate Image Assessment
iRhythm Holdings, Inc. has cultivated a strong brand reputation based on its technological innovation and market presence with the Zio System. The company's proprietary technology has garnered clinical acclaim and established its services as a preferred choice for clinicians diagnosing arrhythmias. However, the company has faced some challenges that could impact its reputation, including potential repercussions from a Department of Justice inquiry and an FDA warning letter with Form 483 observations.
Ownership
iRhythm Holdings, Inc.'s ownership structure is heavily weighted towards institutional investors, including Vanguard Group Inc and BlackRock, Inc.. Significant individual or insider owners include Synergy Life Science Partners L P, Holdings A. Novo, and New Leaf Ventures II LP. CEO Quentin Blackford directly owns approximately 0.28% of the company's shares.
